Table 1. Grade of p130Cas expression in primary and relapsing breast cancer patients before and after trastuzumab treatment.
| Case N° | Stage | Histology | Mol. Subtype | Surgery at diagnosis | p130Cas (IHC before trastuzumab | p130Cas (IHC) after trastuzumab |
|---|---|---|---|---|---|---|
| 1 | III | CDI | HER2-Enriched | Yes | 2+ | 3+ |
| 2 | III | CDI | HER2-Enriched | Yes | 1+ | 3+ |
| 3 | III | CLI | HER2-Enriched | Yes | 1+ | 3+ |
| 4 | III | CDI | HER2-Enriched | Yes | 3+ | 3+ |
| 5 | III | CDI | HER2-Enriched | Yes | 2+ | 3+ |
| 6 | III | CDI | Luminal-HER2 | Yes | 1+ | 3+ |
| 7 | III | CDI | Luminal-HER2 | Yes | 2+ | 3+ |
| 8 | IV | CDI | Luminal-HER2 | Not | 3+ | 3+ |
| 9 | I | CLI | HER2-Enriched | Yes | 1+ | 2+ |
| 10 | III | CDI | HER2-Enriched | Yes | 2+ | 3+ |
| 11 | III | CDI | HER2-Enriched | Yes | 2+ | 2+ |
CDI: Ductal Infiltrating Carcinoma; CLI: Lobular Infiltrating Carcinoma; IHC: immunohistochemistry.